Aim: This is a retrospective review of all SCLC patients prospectively evaluated for second-line treatment between 2003 and 2013 at our Institution. The aim of this study is to assess the feasibility of second-line treatment with Epirubicin(E) plus Paclitaxel(P) in terms of RR, DCR, PFS, OS, and safety. (N=58) consisted on grade (G)3 anemia, leucopenia, and neutropenia in 5(9%), 12(21%), 19 (33%) patients respectively, without G3 thrombocytopenia; we observed G4 leucopenia, neutropenia and thrombocytopenia in 6(10%), 11(19%) and 2(3%) patients respectively. Among patients evaluable for non-haematological toxicity (N=62), G3 neurological toxicity was present in 1(2%) patient, while 2(3%) cases of cardiotoxicity were shown:one patient had a G1 systolic function reduction and a cardiac ischemia occurred in the second patient after one cycle of study treatment.
